# Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2

> **NCT07531979** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 93 (estimated)

## Conditions studied

- ESCC
- Tislelizumab
- Chemotherapy
- Becotatug Vedotin
- EGFR ADC
- PD-1 Inhibitor

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Becotatug Vedotin
- **DRUG:** Cisplatin
- **DRUG:** Tislelizumab
- **DRUG:** Becotatug Vedotin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07531979
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07531979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07531979, "Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07531979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*